SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network ($AVT.X) is trending as traders discuss its potential for a breakout, pointing to its strong chart setup and real-world partnerships. Community members are drawn to its low market cap, integration with Polkadot, and enterprise use cases, suggesting it may be undervalued. Volume is a key point of focus, as traders anticipate it could drive significant price movement.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to recent Phase 2 trial data for its skin drug, sonelokimab, showing positive results in hidradenitis suppurativa. The community is discussing the drug's efficacy compared to competitors and speculating about a potential buyout, possibly by Merck, despite a higher-than-expected placebo response in one trial. Some traders are wary of the trial data, while others see long-term potential.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Despite a recent offering, Cipher Mining is trending as investors see a bullish signal due to its partnership with Google and expansion into high-performance computing. The community is actively discussing the potential for significant growth, especially with the zero-interest funding deal and capped call protections against dilution. Some investors believe Cipher Mining is undervalued, positioning itself as a key player in AI infrastructure rather than just Bitcoin mining.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to a recently announced private placement of approximately $44 million, leading to significant after-hours price movement. Community discussion revolves around the potential for continued momentum, the impact of the offering, and possible short squeeze opportunities. Some traders are also noting potential dilution from warrants associated with the deal.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as a crypto emphasizing community, culture, and freedom within the cannabis space. Community members highlight Weedcoin as more than just a token, but a movement to connect people and ideas. With the hashtags #Weedcoin #CryptoCulture #Growth, the community is focused on building a positive and inclusive environment.

Advisorshares Trust - AdvisorShares MSOS 2x Daily ETF

AdvisorShares MSOS Daily Leveraged ETF

The AdvisorShares MSOS Daily Leveraged ETF ($MSOX) is trending due to renewed speculation around potential cannabis rescheduling and safe banking, with investors actively discussing entry points and potential upside. Bullish sentiment is building as traders anticipate a sector-wide rally, while some express concerns about the ETF's performance and correlation with its underlying assets. Community members are also weighing potential political catalysts and the impact of key figures on the industry's future.

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Merus N.V

Recent buzz around Merus (MRUS) is driven by buyout rumors, with Genmab reportedly leading the acquisition race, exciting retail traders. The community is also discussing Barclays' initiation of an Overweight rating with a $112 price target. Some traders are highlighting the potential of Merus's pipeline and multispecific antibody platform.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending following positive phase 3 trial results for its oral Wegovy pill, showing significant weight loss, which could broaden its market appeal; the community is weighing its potential against competitor Eli Lilly. Community members are also digesting news of job cuts impacting the US obesity education team amid an increasingly competitive GLP-1 market.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics ($AAOI) is trending due to its announcement of the first volume shipment of data center transceivers to a major hyperscale customer, signaling a re-engagement after several years. Bullish sentiment is fueled by expectations of significant business opportunities and increased demand for AI infrastructure, although some analysts remain cautious. The community is actively discussing potential upside, with some expecting a return to higher price levels amid speculation about customer identity and potential for a short squeeze.

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Illumina Inc

ILMN is trending as the market digests news of the completed spin-off of GRAIL, with community chatter focusing on the stock's potential to unlock value post-separation. Community members are weighing bullish sentiments against recent price target revisions and broader sector volatility. Discussions also include potential impacts from competitor activities and the company's strategic positioning within the AI-driven genomics landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome Shares Up 20% in a Month: How Should You Play the Stock?

AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.

Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings

While the top- and bottom-line numbers for Axsome (AXSM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates

Axsome (AXSM) delivered earnings and revenue surprises of +8.00% and +7.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study

Alkermes falls 8.8% despite alixorexton hitting key goals in a narcolepsy type 1 study, as cataplexy data stirs investor concerns.

Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment

HRMY isn't your typical cannabis play - its synthetic CBD gel targets rare brain disorders with no approved therapies.

Shares of Axsome Therapeutics, Inc. (AXSM) slumped 3% in the pre-market session on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/09/3095729/33090/en/Axsome-Therapeutics-Provides-Update-on-the-New-Drug-Application-NDA-for-AXS-14-for-the-Management-of-Fibromyalgia.html">said</a> that it has received a Refusal-to-File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its application for a drug approval to treat fibromyalgia.The FDA issues refuse-to-file letters if it identifies deficiencies in a company’s application for drug approval.The agency said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review.The FDA noted that it does not consider the second of the two placebo-controlled trials in the submission to be adequate and well-controlled because its primary endpoint was at eight weeks, and it used a flexible-dose paradigm.The agency, however, opined that the first of the two placebo-controlled trials in the submission, which utilized a 12-week endpoint and a fixed-dose paradigm, is adequate and well-controlled. Both studies yielded positive results. &nbsp;To address the FDA’s feedback, Axsome will conduct an additional controlled trial, utilizing a fixed-dose paradigm and a 12-week primary endpoint. The company anticipates initiating the new trial in the fourth quarter of 2025.CEO Herriot Tabuteau said that the company is “well-positioned” to initiate the new trial.Fibromyalgia is a chronic disorder characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment. Approximately 17 million Americans, 90% of whom are women, are estimated to suffer from the disorder.On Stocktwits, retail sentiment around Axsome stayed unmoved within the ‘bullish’ territory over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_09_at_8_04_44_AM_png_5593dd0fd5.webp" alt="AXSM's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 9, 2025 | Source: Stocktwits" width="627" height="63"><figcaption>AXSM's Sentiment Meter and Message Volume as of 8:05 a.m. ET on June 9, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the possibility for the company achieving profitability by the end of the year is “out the window.”<stembedurl>https://stocktwits.com/GrayCapital/message/617244353</stembedurl>Another user, however, brushed it off as a “small delay.”<stembedurl>https://stocktwits.com/cadbrad1/message/617242242</stembedurl><a href="https://stocktwits.com/symbol/AXSM">AXSM stock</a> has risen by about 28% this year and by about 56% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-higher-ahead-of-us-china-talks/chlEazYRbyd">Dow Futures Edge Higher Ahead Of US-China Talks In London: WBD, Apple, Tesla Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Axsome Therapeutics company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability

The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review.

Equity

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.83	--	--	N/A
Q2 '25	-$1.05	-$0.97	7.36%	BEAT
Q1 '25	-$1.35	-$1.22	9.71%	BEAT
Q4 '24	-$1.00	-$1.54	-53.85%	MISSED
Q3 '24	-$1.38	-$1.34	3.14%	BEAT

AXSM
Axsome Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest AXSM News

AXSM Axsome Therapeutics Inc